08:44 AM EDT, 10/28/2025 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) reported Q3 earnings Tuesday of $0.06 per diluted share, swinging from a loss of $0.33 a year earlier.

Four analysts polled by FactSet expected a loss of $0.10.

Revenue for the quarter ended Sept. 30 was $99.2 million, compared with $44.8 million a year earlier.

Analysts polled by FactSet expected $87 million.

For 2026, Arcutis said it expects net product revenue to be between $455 million and $470 million.

Shares of the company rose more than 15% in recent premarket activity on Tuesday.

Price: 22.75, Change: +3.11, Percent Change: +15.84